On Friday, Shares of Kitov Pharmaceuticals Holdings LTD (NASDAQ:KTOV) surged 27.83% to $4.72. There is no special news release for the company today.
The surge in share price is referred as technical surge.
The company most recent volume stood at 1,281,359 shares as contrast to average volume of 71,034 shares. Over the one year trading period, the stock has a high price of $5.70 and its low price is recorded at $2.20. The company has a market cap of $2.91M.
The year-to-date performance of the company stands at 17.46% with an advance of 16.72% in the last week and -8.42% in the previous three months.
Kitov Pharmaceuticals Holdings LTD (NASDAQ:KTOV) has EPS ratio of -7.94. The stock has a consensus analyst price target of $10 for twelve month.
Kitov Pharmaceuticals Holdings Ltd. engages in developing non-steroidal anti-inflammatory drugs that treat the pain of osteoarthritis without causing cardiovascular problems. It is developing KIT-301 and KIT-302 drugs for the treatment of osteoarthritis. The company was formerly known as Mainrom Line Logistics Ltd. and changed its name to Kitov Pharmaceuticals Holdings Ltd. in August 2013. Kitov Pharmaceuticals Holdings Ltd. is based in Jerusalem, Israel.
Shares of Eclipse Resources Corporation (NYSE:ECR) declined -10.46% to $1.37. There is no special news for the company.
Eclipse Resources Corporation declared the participation of members from the Company’s executive administration team in the following forthcoming shareholder conferences:
Wednesday March 23, 2016 (New Orleans, LA) – Scotia Howard Weil Energy Conference. Benjamin W. Hulburt (Chairman, President and CEO) will present at 10:45 am Central Time and will host one-on-one meetings with Matthew R. DeNezza (Executive Vice President and CFO).
Tuesday April 12, 2016 (New York, NY) – IPAA OGIS Conference. Benjamin W. Hulburt (Chairman, President and CEO) will present at 3:15 pm Eastern Time and will host one-on-one meetings with Matthew R. DeNezza (Executive Vice President and CFO).
On March 2, Eclipse Resources Corporation declared its fourth quarter and full year 2015 financial and operational results, its 2016 Capital Budget, the reaffirmation of its revolving credit facility borrowing base and updated first quarter and full year 2016 guidance.
Revenues for the fourth quarter of 2015 totaled $65.9 million, representing a 31% increase as contrast to revenues for the fourth quarter of 2014. Adjusted Revenue, which includes the impact of cash settled derivatives, and excludes brokered natural gas and marketing revenue, totaled $74.4 million, representing a 41% increase over Adjusted Revenue of $52.6 million in the fourth quarter of 2014. The net loss for the fourth quarter of 2015 was $813.9 million, or $3.66 per share. Adjusted EBITDAX was $31.3 million for the fourth quarter of 2015, or $0.14 per share.
Source: Wall Street 24